MedTrace Logo

First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer

NCT05648006 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2024-04-30

No results posted yet for this study

Summary

This is a prospective, multicenter, open, randomized controlled Phase II clinical study to evaluate the efficacy and safety of intratumoral injection of OH2 combined with capecitabine for first-line maintenance of advanced colorectal cancer.

Conditions

  • Advanced Colorectal Carcinoma

Interventions

BIOLOGICAL

OH2

Oncolytic Type 2 Herpes Simplex Virus

DRUG

Capecitabine

1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks

DRUG

Bevacizumab

Bevacizumab: 7.5 mg/kg, intravenously, once every 3 weeks.

Sponsors & Collaborators

  • Binhui Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-17
Primary Completion
2024-04-15
Completion
2024-04-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05648006 on ClinicalTrials.gov